European Psychiatry - Volume 41 - April 2017

829 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S772–S846 S825
faced with reality, these patients are unable to adjust themselves
and frequently are negativistic to offered help and therapies.
Conclusion We assume that paranoid patients should be treated
not with straightforward strategies, such as psychoeducation, but
with less stigmatizing methods that work on metacognitive and
motivational levels.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1282
A systematic review of the
pharmacological treatment of
delusional disorder
J.E. Mu˜noz Negro ∗, J. Cervilla
1 Andalusian Health Service-CIBERSAM, University of Granada,
Mental Health Unit. University Hospital Complex of Granada,
Granada, Spain
2 Andalusian Health Service, CIBERSAM. University of Granada,
Mental Health Unit, University Hospital Complex of Granada,
Granada, Spain
∗ Corresponding author.
Introduction Pharmacological treatment is the gold standard in
delusional disorder (DD), moreover the second generation antipsy-
chotics (SGA) arewidely used in the treatment of DD, in spite of this,
none SGA is authorized for the treatment of DD.
Objectives To evaluate the evidence available for pharmacologi-
cal treatment in adults with DD. Especially, that concerning SGA.
Methods A systematic review on pharmacological treatment of
DD was conducted. We selected the best evidence available. Then,
we analysed them critically, assessing its biases and quality, finally
performed a narrative and quantitative synthesis.
Results The quality of the evidence was very low. There were
not randomized clinical trials. n = 385, 177 SGA. Antipsychotics
achieved a good response in a 33.6% of the patients. First gener-
ation antipsychotics (FGA) did show superiority compared to SGA
(39% good response vs. 28%, respectively. P ≤ 0.02). We could not
find data about superiority of any drug over other. Pimozide, tra-
ditionally considered the most effective drug, did not confirm to
be a superior treatment compared to others. Reasons for superi-
ority of FGA were analyzed. The role of another treatments were
testimonial, but antidepressants can be a promising treatment.
Conclusions There is no evidence to make strong recommenda-
tions, although antipsychotics in general appear to be an effective
treatment for DD. Superiority of FGA against SGA was shown. We
need to develop clinical trials in DD and SGA, since their better
tolerance profile might be the best candidates to do.
Keywords Delusional disorder; Pharmacological treatment;
FGA; SGA
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1283
Seroprevalence of toxoplasma gondii
in Romanian psychiatric patients
T.R. Olariu ∗ . Capraru apava Romosan
L. Dehelean A. Lupu
1 University of Medicine and Pharmacy “Victor Babes”, Parasitology,
Timisoara, Romania
2 University of Medicine and Pharmacy “Victor Babes”, Department of
Neurosciences, Discipline of Psychiatry, Timisoara, Romania
∗ Corresponding author.
Introduction Toxoplasma gondii infectionhas been recently asso-
ciated with schizophrenia and other psychiatric disorders.
Aim The aim of the present study was to evaluate the preva-
lence of T. gondii antibodies among acute psychiatric patients from
Western Romania.
Methods This study included 214 consecutive patients admitted
at the psychiatric clinic, Country Clinical Emergency Hospital in
Timisoara, Romania, between 30.06.2011 and 12.01.2012. Clinical
and laboratory investigations were performed in these hospital-
ized patients, including serologic tests for T. gondii IgG and IgM
antibodies.
Results The 214 patients aged 19 to 71 years (mean = 42.5), 64.9%
were females. T. gondii antibodies were detected in 117 (54.7%) of
214 psychiatric patients. When the data were analyzed by diagnos-
tic groups, T. gondii antibodieswere demonstrated in 30 (50.84%) of
59 patients with schizophrenia, in 28 (59.57%) of 47 with persistent
delusional disorder, 10 (31.25%) of 32 with acute and transient psy-
chotic disorder, 13 (54.16%) of 24 with schizoaffective disorder and
35 (70%) of 50 with bipolar disorder. A high prevalence of T. gondii
antibodies was found among patients with bipolar disorder com-
pared to those with schizophrenia (P = 0.043) acute and transient
psychotic disorder (P < 0.0001) and healthy controls (P < 0.0001). Of
the 18 patients with schizophrenia and a BPRS score <51, T. gondii
antibodies were detected in 13 (72.2%) compared to 17 (41.4%) of
41 in whom BPRS score was >51 (P = 0.03).
Conclusion These findings suggest that T. gondii infection may
be associated with several psychiatric disorders. A high sero-
prevalence of T. gondii was demonstrated in patients with bipolar
disorder.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1284
A descriptive study of a sample of 42
male outpatients diagnosed psychotic
disorder
M.D. Ortega Garcia ∗ . Marti Garnica arcia Marin
C. Martinez Martinez lanco del Valle omez Martinez
M.A. Lopez Bernal
1 CSM Cartagena, Child and Adolescent Mental Health Centre,
Cartagena, Spain
2 CSM Lorca, Psychiatry, Lorca, Spain
3 CSM Leon, Psychiatry, Leon, Spain
4 CSM Soria, Psychiatry, Soria, Spain
5 CSM Cartagena, Psychiatry, Cartagena, Spain
∗ Corresponding author.
Aims The approach to mental illness and specifically in serious
mood disorders, long-term treatments that improve adhesion as
continuous treatments ensure compliance are needed, they mini-
mize the risk of relapse and readmission and therefore increase the
chances to have a good fit and social, relational and even occupa-
tional functioning.
Method We analysed a sample of 42 male diagnosed with
schizophrenia, schizoaffective disorder, chronic delusional dis-
order that starts treatment with Paliperidone Palmitate in
outpatients. It is analysed the dose of paliperidone palmitate
employed for stabilization and family satisfaction at the time of
stabilization is analysed in the study.
Results The mean dose of Paliperidone Palmitate is 138mg. The
patient diagnosed with schizophrenia are 47.6% and the average
dose is 132.5mg. Chronic delusional disorder is 2.3% and the mean
dose 50mg. Other comorbility mood disorders are 21.4% and the
mean dose is 183mg. Other disorders (F70, F72. . . ) are 28.5% and
mean dose 133mg. The average family satisfaction (minimum 1 up
to 5) is 4, with the highest score among patients diagnosed with
F20 Schizophrenia.
Conclusions Long lasting injectable medications achieve impor-
tant adherence and a high percentage of antipsychotic monother-